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Abstract: Age-related macular degeneration (AMD), the most common visual disorder in elderly
people, is characterized by the formation of deposits beneath the retinal pigment epithelium (RPE)
and by dysfunction of RPE and photoreceptor cells. The biologically active form of vitamin D,
1,25-(OH)2D3 (VITD), is categorized as a multifunctional steroid hormone that modulates many
transcriptional processes of different genes and is involved in a broad range of cellular functions.
Epidemiological and genetic association studies demonstrate that VITD may have a protective role in
AMD, while single nucleotide polymorphisms in the vitamin D metabolism gene (CYP24A1) increase
the risk of AMD. However, the functional mechanisms of VITD in AMD are not fully understood.
In the current study, we investigated the impact of VITD on H2O2-induced oxidative stress and
inflammation in human RPE cells. We demonstrate that exposure to H2O2 caused significantly
reduced cell viability, increased production of reactive oxygen species (ROS), lowered expression of
antioxidant enzymes and enhanced inflammation. VITD exposure notably counteracted the above
H2O2-induced effects. Our data suggest that VITD protects the RPE from oxidative damage and
elucidate molecular mechanisms of VITD deficiency in the development of AMD.
Keywords: vitamin D; oxidative stress; inflammation; retinal pigment epithelial cells; age-related
macular degeneration
1. Introduction
Age-related macular degeneration (AMD) is an accelerating neurodegenerative ocular disease that
affects people above 55 years of age [1]. Epidemiologic studies have shown that there is an increasing
number of new AMD cases diagnosed worldwide annually [2]. Wong et al. (2014) reported that the
incidence of AMD is 7.1% in the African, 6.81% in the Asian, 11.19% in the Caucasian and 9.87%
in the Hispanic population [3]. Several risk factors, such as smoking, have been associated with
increased incidence of AMD [2]. A number of studies have suggested that the incidence of AMD is
also linked to genetic defects [1,2]. It has been proposed that the AMD genetic association is strongly
related to genetic defects in ARMS2/HTRA1 and CFH located on, respectively, chromosome 10q26 and
1q32 [1,2]. Although the pathological mechanisms of AMD are not fully understood, many studies
have suggested that AMD is an inflammatory process that involves increased production of many
inflammatory mediators such as tumor necrosis factor-α (TNF-α), interleukins-1β, 6, 8 and 33 (IL-1β,
IL-6, IL-8 and IL-33) [1,4], vascular endothelial growth factor A (VEGFA) [5] and activation of the
alternative complement pathway [6].
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Vitamin D is a fat-soluble secosteroid molecule that is found in two forms: vitamin D2 and
vitamin D3 [7]. The latter is more abundant than vitamin D2 in biological systems; thus, vitamin
D3 is commonly referred to simply as vitamin D. Humans and higher mammals can obtain vitamin
D from various nutritional sources such as meats and fungi [7]. In addition, vitamin D can be
produced endogenously. The endogenous synthesis of vitamin D starts in the epidermal skin layers
where the vitamin D precursor 7-dehydrocholesterol (7-DHC) is converted to pre-vitamin D3 through
a photoisomerization process activated by exposure to type B ultraviolet radiation (UVB) between
280 and 320 nm, then incorporated with its carrier globin, vitamin D binding protein (DBP), and
transported to the liver [7]. The pre-vitamin D3 is transformed to 25-dihydroxyvitamin D3 through
the hepatic cytochrome P450 hydroxylase enzymes microsomal CYP2R1 and mitochondrial CYP2A1,
attached to DBP and transported to the kidney [7]. Finally, 25-dihydroxyvitamin D3 is converted to the
active form 1,α,25-dihydroxyvitamin D3 (1,25(OH)2D3) in renal cells by mitochondrial 1,α, CYP27B1.
This step is tightly regulated by parathyroid hormone (PTH) and by circulating levels of calcium
and phosphate, as well as by 1,25(OH)2D3 itself [7]. The molecule 1,α,25-dihydroxyvitamin D3 is
well recognized as a steroid hormone that regulates many cellular signalling activities through its
nuclear vitamin D receptor (VDR) in target cells [7,8]. Vitamin D deficiency in the general population is
currently considered a global health concern and represents a risk factor for the development of many
diseases, particularly neurodegenerative diseases [9]. A large number of studies have shown that the
likelihood of AMD is increased among those individuals with low circulating vitamin D levels [10–13].
IL-33 is a member of the IL-1 cytokine family that is expressed in many cell types of the nervous
system [14]. IL-33 signalling is mediated through binding to its ST2 receptor in target cells and
recruiting transcriptional cofactors such as IL-1R accessory protein (IL-1RAP), IL-1R-associated kinases
1/4 (IRAK1/4) and myeloid differentiation primary-response protein 88 (MYD88) into the transcription
complex [14,15]. This cytokine has important roles in the inflammatory response in the modulation of
neurodegenerative diseases, e.g., Alzheimer’s disease [16] and AMD [4].
In the current study, we investigated the role of vitamin D in oxidative stress and inflammation.
We found that vitamin D increased cell viability, reduced the formation of reactive oxygen species
(ROS), and inhibited inflammation. Vitamin D also stimulated the expression of IL-33 at the mRNA
and protein levels. Furthermore, IL-33 treatment markedly induced the expression of antioxidant
genes. Our data suggest that the protective effects of vitamin D in AMD may be partially through the
upregulation of IL-33.
2. Materials and Methods
2.1. Cell Culture
ARPE-19 cells (ATCC® CRL-2302™, ATCC, Manassas, VA, USA) were grown in a T-25 cm2
standard tissue culture flask in 5 mL of DMEM/F12 medium containing 2.4 mM L-Glutamine, 15 mM
Hepes, 17.5 mM glucose, 10% FBS, 50 IU/mL of Penicillin and Streptomycin and 17.4 mL of 7.5%
Sodium bicarbonate. The cells were maintained in a 5% CO2 incubator at 37 ◦C. Once cell growth
reached 80–90% confluency, the medium was removed and the cells were washed twice with PBS.
The cells were then trypsinized with 1–1.5 mL of 0.5% trypsin–EDTA. Detached cells were resuspended
in 4–5 mL of DMEM/F12 medium and seeded in 96- or 6-well tissue culture plates for 24 h at a density
of 50,000 or 500,000 cells per well prior to cell treatment.
2.2. Cell Viability Assay
ARPE-19 cells were seeded at a density of 50,000 cells per well in a 96-well plate in DMEM/F12
medium for 24 h. The medium was then removed, and the cells were washed twice with 0.5 mL of
1× PBS/well. The cells were then treated with serial concentrations of H2O2 (150–2000 µM), 50 nM 1α,
25(OH)2D3 (VITD), 0.1% ethanol for 6 and 24 h (or left untreated for the same time periods). In some
experiments, ARPE-19 cells were treated with 750 µM H2O2, 750 µM H2O2 + 50 nM VITD, or left
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untreated. All treatments were performed in serum-free DMEM/F12 medium. The cell viability assay
was performed as previously described [17].
2.3. Caspase-3/7 Activity
ARPE-19 cells were seeded in a 96-well plate (20,000 cells/well) overnight and treated with
750 µM H2O2, 750 µM H2O2 + 50 nM VITD, or 0.1% DMSO (control). Caspase-3/7 activity was
measured by the Apo-ONE Homogeneous Caspase-3/7 kit (Promega, Southampton, UK) according to
the manufacturer’s instructions. Fluorescence was measured using a Fluostar Optima Plate Reader
at an excitation wavelength of 499 nm and an emission wavelength of 521 nm. Caspase-3/7 activity
was determined according to the following formula: % relative fluorescence = (fluorescence of treated
cells − fluorescence of control cells)/fluorescence of control cells × 100. All experiments were repeated
three times.
2.4. Measurement of Reactive Oxygen Species (ROS)
ARPE-19 cells were cultured at a density of 25,000 cells per well in a 96-well plate and treated
with 750 µM H2O2, 750 µM H2O2 + 50 nM VITD, or 0.1% DMSO for 6 and 24 h. Production of ROS
was measured using the 6-Carboxy-2′,7′-Dichlorofluorescin diacetate (DCFH-DA) dye (Sigma, Dorset,
UK). The medium was removed, and the cells were washed twice with 1× PBS, 200 µL/well. Then,
150 µL of 10 µM DCFH-DA in 1× PBS/well was added, and the plate was incubated for 45 min in
a 5% CO2 incubator at 37 ◦C. Fluorescence was measured at 485 nm (excitation) and 525 nm (emission)
using a Fluostar Optima microplate reader (BMG LABTECH Ltd, Bucks, UK). The ROS level was
represented as the percentage of fluorescence intensity relative to the control after baseline fluorescence
correction according to the following formula: (fluorescence of treated cells − fluorescence of control
cells)/fluorescence of control cells × 100. All experiments were repeated three times.
2.5. Enzyme-Linked Immunosorbent Assay (ELISA)
Total proteins from ARPE-19 cells, retina and RPE were extracted by homogenizing samples in
200 µL of T-PER buffer containing 1× protease Inhibitor Cocktail. The supernatants were collected
by centrifugation at 10,000 rpm for 5 min. The concentration of IL-1β, IL-8, IL-33, TNFα and VEGFA
in control and treated human ARPE-19 cell media was measured using commercial ELISA kits from
PeproTech and eBioscience according to the manufacturer’s protocols. The levels of the examined
cytokines were quantified using a standard curve constructed on the basis of the mean absorbance of
standard solution concentrations of cytokines (X axis) against optical density (O.D). for each standard
solution (Y axis). The concentration of unknown samples (pg/mL) was calculated on the basis of
the straight line equation obtained from the linear-regression trendline according to Y = mx + c
(where Y = O.D. of unknown sample, m = slope value, x = concentration of unknown sample and
c = intercept). All experiments were repeated three times.
2.6. Biochemical Assay
Quantification of malondialdehyde (MDA) and glutathione (GSH) and measurement of
CATALASE and superoxide dismutase (SOD) activities were performed using kits from CELL
BIOLABS INC (San Diego, CA, USA) according to the manufacturer’s instructions.
2.7. Mouse Samples
Mice used in this study were housed in the Animal Unit at Glasgow Caledonian University
with free access to food and water and a 12 h light/dark environment. Mice at the age of 2 months,
9 months and 24 months were sacrificed, and the retina and RPE were dissected and stored at −80 ◦C
for further analysis. Approval for animal use was granted by the Glasgow Caledonian University
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Animal Ethics and Welfare Committee, in accordance with the UK home office animal care guidelines
(Project licence P8C815DC9).
2.8. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Total RNAs from ARPE-19 cells and mouse tissues (retina and RPE) were extracted using Tri
Reagent® (Sigma, Dorset, UK) following the manufacturer’s instructions. The cDNA was synthesized
using the High-Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific, Paisley, UK) as
described by the manufacturer. Quantification of gene expression was performed using real-time PCR
Platinum SYBR Green qPCR SuperMix-UDG with ROX assay, as described by the manufacturer. Briefly,
1.0 µL of 50 ng/µL of cDNA was mixed with 7.5 µL of Platinum SYBR Green qPCR SuperMix-UDG
with ROX and 0.6 µL of 10 µM forward and reverse primers, and the reaction volume was scaled to
15 µL with nuclease-free water. DNA amplification was carried out under the following conditions:
50 ◦C for 2 min (UDG incubation), followed by enzyme activation at 95 ◦C for 2 min, hold and then
an amplification step of 40 cycles including DNA denaturation at 95 ◦C for 15 s, then primer annealing
at 60 ◦C for 15 s. Fluorescence signals were detected at the end of the 60 ◦C step, and assay validity
was assessed on the basis of the melting curve analysis following each run. Relative gene expression
was determined according to the 2−∆∆ct formula. The primer sequences for qRT-PCR are available
on request.
2.9. Immunostaining
ARPE-19 cells were fixed with methanol at −20 ◦C for 5 min, then washed with 1× PBS twice.
The cells were blocked with 2% BSA-PBS at room temperature for 30 min, then incubated with primary
antibodies at 4 ◦C overnight. After washing three times (5 min each time), the cells were blocked again
with 2% sheep serum in 2% BSA-PBS for 30 min. The cells were incubated with secondary antibodies
at room temperature for 1 h, then washed 5 times with 1× PBS (5 min each). The cells were mounted
with DAPI solution and imaged under a confocal microscope.
2.10. Western Blot
Treated and control cells were lysed with Radio-Immuno Precipitation Assay (RIPA) buffer.
Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. The targeted
proteins were detected using primary antibodies (NRF2, 1:1000; GAPDH, 1:1000) and secondary
antibodies (1:10,000). The signals were quantified with the ImageStudio™Lite analysis software
(LI-COR, Cambridge, UK).
2.11. Statistical Data Analysis
Data were analysed by one-way or two-way Anova followed by Bonferroni post-hoc test using
GraphPad Prism version 6 software (GraphPad Software Inc., San Diego, CA, USA); p < 0.05 was
considered significant. All experiments were repeated three times.
3. Results
3.1. VITD Treatment Improved Cell Viability and Reduced ROS Production and Apoptosis
In order to determine the appropriate concentration of H2O2 to induce a significant, though
not excessive, toxic effect on cell viability, ARPE-19 cells were challenged with H2O2 at a range of
concentrations (150 to 2000 µM) for 6 or 24 h. We detected a significant reduction in cell viability in cells
treated with 450, 600, 750 and 1000 µM H2O2 for 6 and 24 h compared to the respective control cells.
A concentration of H2O2 higher than 1000 µM was determined to be highly toxic (Figure S1). Thus,
750 µM H2O2 was used to treat ARPE-19 cells for all subsequent experiments in this study. We also
chose 50 nm VITD for our current study on the basis of earlier in vitro studies [18,19]. We found
that 50 nM VITD significantly increased the viability of treated ARPE-19 cells when compared to
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untreated control cells (Figure S1). Previous studies reported that VITD treatment can protect cells and
tissues from oxidative damage [20–23]. In the current study, treatment of ARPE-19 cells with 750 µM
H2O2 for both 6 and 24 h caused a significant reduction in cell viability and a significant increase
in ROS production (Figure 1A,B). The latter can activate apoptosis signalling pathways [24]. In the
current study, caspase 3/7 activation, an indicator of apoptosis, was significantly increased in cells
exposed to 750 µM H2O2 for both 6 and 24 h (Figure 1C). When H2O2 exposure was accompanied by
a treatment with VITD, the above effects were reversed: there was a significant increase in cell viability,
a significant decrease in ROS production and a significant decrease in caspase 3/7 activation, compared
to the levels seen following treatment with H2O2 alone (Figure 1A–C). Increased ROS can promote
lipid peroxidation, resulting in increased production of MDA and 4-hydroxynonental (4-HNE), which
indicates local cell or tissue damage. We found that MDA production in ARPE-19 cells treated with
H2O2 was significantly higher than that seen in untreated cells; co-treatment with VITD significantly
counteracted this effect (Figure 1D).
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Figure 1. Effects of vitamin D (VITD, 1,25(OH)2D3) on cell viability, reactive oxygen species (ROS)
production, apoptosis and malondialdehyde (MDA) level. ARPE-19 cells were treated with H2O2 alone
or with H2O2 + VITD for 6 h or 24 h. Cell viability (A), ROS production (B), Caspase 3/7, a biomarker
of apoptosis (C), and MDA, a biomarker of lipid peroxidation, levels (D) were examined. Data are
presented as the means ± standard deviation (SD) of three independent experiments. UT: untreated
control. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
3.2. VITD Treatment Enhanced VDR) Expression in Stressed ARPE-19 Cells
VDR is the principal nuclear receptor for VITD signalling in biological systems [7,8]. It is expressed
in many cells includi g retinal and RPE cells [25–27]. Our current results show that VDR was expressed
in untreated (control) ARPE-19 cells, in cells treated with H2O alone and in cells co-treated with H2O2
and VITD (Figure S2A). This expression was significantly reduced (upon both 6 and 24 h exposure) in
ARPE-19 cells treated with 750 µM H2O2 compared to untreated cells; however, VDR expression was
substantially incr ased (upon both 6 and 24 h exposure) in ARPE-19 cells co-treat d with 750 µM H2O2
and 50 nM VITD compared to cells treated with 750 µM H2O2 alone (Figure S2B).
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3.3. VITD Treatment Upregulated the Expression of Antioxidant Genes
Increased intracellular ROS production associated with many pathological conditions can cause
major cellular injury, reducing cells’ capacity to produce protective molecules such as anti-oxidant
proteins [28]. Recent studies have shown that VITD treatment can modulate both gene expression and
activity of many antioxidant molecules [29–31]. In the current study, we used qRT-PCR to examine the
expression of SOD1, SOD2, CATALASE (CAT), GPX1, GPX2 and GPX3 genes in ARPE-19 cells under
our stress condition and VITD treatment. We found that, at both 6 and 24 h, the expression of CAT,
SOD1, SOD2, GPX2 and GPX3 were noticeably reduced in ARPE-19 cells treated with 750 µM H2O2
compared to untreated cells; however, the expression of these antioxidant genes was significantly
increased in ARPE-19 cells co-treated with 750 µM H2O2 and 50 nM VITD compared to cells treated
with 750 µM H2O2 alone (Figure 2A). There was no significant difference at 6 or 24 h in GPX1 expression
in untreated cells, cells treated with 750 µM H2O2 alone, and cells co-treated with 750 µM H2O2 and
50 nM VITD (Figure 2A).
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Figure 2. VITD treatment enhanced the expression of antioxidant genes. (A) ARPE-19 cells were
exposed to H2O2 alone or H2O2 + VITD for 6 h or 24 h. The expression of SOD1, SOD2, CATALASE
(CAT), GPX1, GPX2 and GPX3 in treated and untreated cells was measured by qRT-PCR. (B) ARPE-19
cells were exposed to H2O2 alone or H2O2 + VITD for 24 h; the activities of SOD and CAT and GSH
level were biochemically examined. Data are presented as the means ± standard deviation (SD) of
three independent experiments. UT: untreated control. ns: no significance. * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001.
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We also examined the effect of VITD treatment on SOD and CAT activities. The activities of SOD
and CAT were significantly decreased in H2O2-treated cells compared with untreated control cells.
The co-treatment of cells with 750 µM H2O2 and 50 nM VITD resulted in a significant increase in
SOD and CAT activities compared to cells exposed to H2O2 alone (Figure 2B). GSH, an important
intracellular antioxidant, can prevent ROS-induced damage. GSH level was significantly decreased in
H2O2-treated cells compared to untreated control cells, while cells co-treated with VITD and H2O2
showed a significant increase in GSH (compared to cells treated with H2O2 alone (Figure 2B).
3.4. VITD Treatment Modulated the Expression of the Inflammatory Mediators
Recent studies have suggested that AMD is an inflammatory disease that is associated with
increased levels of pro-inflammatory cytokines and the presence of macrophages and other immune
cells [1]. VITD treatment has been shown to regulate the gene expression of many inflammatory
mediators in various biological systems [32]. In this study, we investigated the expression of IL-1β, IL-8,
TNF-α and VEGFA genes in ARPE-19 cells treated with 750 µM H2O2, in cells co-treated with 750 µM
H2O2 and 50 nM VITD, and in untreated control cells. At both 6 and 24 h, the expression levels of IL-1β,
TNF-α, IL-8, IL-18 and VEGFA genes were significantly increased in ARPE-19 cells treated with H2O2
compared to untreated cells; by contrast, at both 6 and 24 h, their expression levels were substantially
reduced in ARPE-19 cells co-treated with 750 µM H2O2 and 50 nM VITD compared to cells treated
with 750 µM H2O2 alone (Figure 3A). We also used ELISA to measure the levels of secreted IL-1β,
IL-8, TNF-α and VEGFA in the media of treated and control cells and found that all the examined
cytokines were significantly increased in ARPE-19 cells treated with 750 µM H2O2 when compared
to control cells; co-treatment with H2O2 and VITD markedly decreased the levels of these cytokines
when compared to cells exposed to H2O2 alone (Figure 3B).Antioxidants 2019, 8, x FOR PEER REVIEW 8 of 15 
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Figure 3. VITD inhibited inflammation. (A) ARPE-19 cells were exposed to H2O2 alone or to
H2O2 + VITD for 6 h or 24 h; the expression of IL-1β, IL-8, TNF-α and VEGF in treated and untreated
cells was measured by qRT-PCR. (B) ARPE-19 cells were exposed to H2O2 alone or to H2O2 + VITD for
24 h. The levels of IL-1β, IL-8, TNF-α and VEGF w re measured by ELISA. Data are pres nted as the
means ± standard deviation (SD) of three ind pendent experiments. UT: untreated control. * p < 0.05,
** p < 0.01, *** p < 0.001, **** p < 0.0001.
3.5. VITD Revers d the H2O2-I hange in NRF2 Expression
NRF2 is a redox-sensitive transcri ti factor that can bind antioxidant eleme ts and activates
the expression of antioxidant and detoxifying enzymes. VITD has been reported to control NRF2
expression [32]. In the current study, when ARPE-19 cells were treated with 750 µM H2O2, NRF2
protein level was significantly decreased compared to untreated control cells; co-treatment with VITD
and 750 µM H2O2 resulted in a marked increase in NRF2 expression when compared to H2O2 treatment
alone (Figure 4).
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Figure 4. H2O2 treatment downregulated NRF2 expression, while VITD reversed the effect. (A) ARPE-19
cells were treated with H2O2 alone or H2O2 + VITD for 24 h; the protein levels of NRF2 in treated
and control cells were examined by Western blotting. (B) NRF2 protein levels were quantified by
normalizing with respect to GAPDH protein. Data are presented as the means ± standard deviation
(SD) of three independent experiments. UT: untreated control. * p < 0.05, **** p < 0.0001.
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3.6. VITD Regulated IL-33 Expression
Previous studies have reported that IL-33 can function as both a proinflammatory and
an inflammatory cytokine during the immune response [15], as anti-apoptotic and survival
molecules [33] can protect from oxidative stress by increasing SOD activity [34] and can attenuate
the development of autoimmune uveitis [35]. IL-33 and its receptor ST2 are abundantly expressed in
many tissues such as the central nervous system and the retina [14,35,36]. We used immunostaining to
detect IL-33 and ST2 expression in ARPE-19 cells and found that IL-33 was localised in the nucleus
(Figure 5A), while ST2 was localised in the cytoplasm, predominantly around the nuclear membrane
(Figure 5B). We also measured IL-33 expression in mouse retina and RPE: the expression of IL-33
decreased in the retina and RPE during ageing (Figure S3). We then examined whether H2O2 and
VITD affect IL-33 expression. Using qRT-PCR, we measured the mRNA level of IL-33 in treated and
control cells and found that IL-33 expression was significantly decreased in ARPE-19 cells treated with
750 µM of H2O2 compared to untreated cells, while it was significantly increased in ARPE-19 cells
co-treated with 750 µM H2O2 and 50 nM VITD compared to cells treated with 750 µM H2O2 alone.
VITD treatment alone for 6 and 24 h also significantly increased IL-33 expression when compared
to control cells (Figure 5C). We also measured the protein level of IL-33 by ELISA: H2O2 treatment
significantly decreased IL-33 level compared to control cells, while co-treatment with H2O2 and VITD
notably counteracted this change. Exposure to VITD alone resulted in a significantly increased IL-33
level compared to the control cells (Figure 5D).Antioxidants 2019, 8, x FOR PEER REVIEW 10 of 15 
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Figure 5. Localization of IL-33 (A) and ST-2 (B) in ARPE-19 cells using immunostaining with anti-IL-33
antibody and anti-ST2 antibody, respectively (63×). (C) Effects of VITD on IL-33 expression in
ARPE-19 cells treated with VITD only, H2O2 alone or H2O2 + VITD for 6 h or 24 h. IL-33 mRNA levels
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were quantified by qRT-PCR. (D) VITD treatment increased IL-33 protein production. ARPE-19 cells
were incubated with VITD only, H2O2 alone or H2O2 + VITD for 24 h. Secreted IL-33 protein was
measured by ELISA. Data are presented as the means ± standard deviation (SD) of three independent
experiments. UT: untreated control. * p < 0.05, ** p < 0.01.
3.7. IL-33 Treatment Upregulated Antioxidant Gene Expression
There is growing evidence that IL-33 can protect cells from apoptosis and oxidative stress and can
enhance cell survival in vitro and in vivo [33,37]. The protective function of IL-33 against apoptosis
and oxidative stress is believed to occur through its action on the gene expression and production of
anti-oxidant scavengers such as superoxide dismutases [34]. In ARPE-19 cells treated with rhIL-33
(10 or 50 ng/mL), the expression of CAT, SOD1, SOD2, GPX2 and GPX3 was significantly increased
following 6 and 24 h treatments. However, there was no significant change in the expression of GPX1
following treatment with either 10 or 50 ng/mL rhIL (Figure 6).Antiox dants 2019, 8, x FOR PEER REVIEW 11 of 15 
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Figure 6. Effects of recombinant human IL-33 on the expression of antioxidant genes. ARPE-19 cells
were treated with recombinant human Il-33 (rhIL-33) for 6 or 24 h. The expression of antioxidant genes
(SOD1, SOD2, CAT, GPX1, GPX2 and GPX3) was measured by qRT-PCR. Data are presented as the
means ± standard deviation (SD) of three independent experiments; ns, no significance. * p < 0.05.
4. Discussion
It is well established that oxidative stress, inflammation and angiogenesis play a critical role in
the development and progression of AMD [38]. VITD has multiple functions including the inhibition
of oxidative stress, inflammation, macrophage activation and angiogenesis, thus offering therapeutic
potential for AMD. Human RPE cell lines can synthesize active vitamin D (VITD), while VDR and
vitamin D synthesis enzymes and metabolism enzymes are also expressed in the neuroretina, RPE
and choroid [38]. Early epidemiological studies showed a connection between vitamin D and AMD,
while genome-wide association studies demonstrated that the vitamin D metabolism ge e (CYP24A1)
is a risk factor for AMD [38–40]. Lee t al. (2012) r ported t at Vita in treatment result d in
decreased retin l nflammation and Aβ deposition and increased visual func ion in aged ice [41].
Pr viously, w r ported th t VITD c n protect con cells from oxidative dam ge [17]. Our current
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data also demonstrate that VITD suppresses oxidative damage and inflammation in RPE cells, further
supporting the hypothesis that VITD may play an important role in AMD.
Although the principal function of the active form of VITD [1,α,25-(OH)2D3] is the regulation
of calcium and phosphate homeostasis, it also acts as a steroid hormone, exerting its effect through
VDR signalling in target cells. The VDR gene is expressed in a number of ocular structures such
as the retina, the cornea and the RPE-choroid and in ocular cell lines such as ARPE-19 and human
retinoblastoma (Y79) [25,39], thus demonstrating its regulatory function in the ocular system. VDR is
one of the nuclear receptors of steroid hormones that mediate transcriptional processes in a variety of
cells. Expression and production of VDR are influenced by factors such as sun exposure, hormones
levels and age. VITD itself also regulates VDR expression through two gene expression enhancers
containing vitamin D3 response element (VDRE): CCAAT/enhancer binding protein-β (C/EBPβ) and
runt-related transcription factor-2 (RUNX2) located upstream of the VDR gene’s transcriptional start
site (TSS) [42,43]. We also confirmed that VITD stimulated VDR expression in ARPE-19 cells (data not
shown) and found that H2O2 treatment significantly decreased VDR expression, while co-treatment
with VITD reversed the H2O2-caused change (Figure S2).
ROS are highly reactive compounds that cause cellular damage through the oxidation of lipids,
proteins and DNA, altering their biochemical characteristics and causing reduced cell viability and
subsequent cell death [44]. Many studies have suggested that VITD can improve cell viability and
protect against the deleterious effects of ROS in various cell lines [20,22,23]. Similarly, in the current
study, a significant reduction of ARPE-19 cell viability was observed in cells treated with H2O2 at
concentrations ranging between 450 and 2000 µM (Figure S1). The reduction in cell viability following
H2O2 treatment was also associated with increased levels of free radicals (ROS) (Figure 1A,B). However,
ROS levels were substantially decreased when ARPE-19 cells were treated with a combination of 750 µM
of H2O2 and 50 nM VITD, suggesting that VITD suppressed H2O2-induced ROS production (Figure 1B).
VITD treatment also inhibited lipid peroxidation and reduced cell death (Figure 1C,D). We also found
that H2O2 exposure reduced the expression of antioxidant genes (SOD1, SOD2, CAT, GPX1, GPX2)
and induced the production of inflammatory cytokines (IL-1β, IL-8, TNF-α and VEGF). Co-treatment
with VITD counteracted these H2O2-induced effects (Figure 2; Figure 3). These protective effects of
VITD against H2O2-induced damage can be explained by its effect on the gene and protein expression
of many antioxidants via upregulation of different transcription factors, e.g., NRF2, a key transcription
factor that modulates the expression of many antioxidants [32]. Our data also demonstrated that H2O2
caused a significant decrease in NRF2 expression, while co-treatment with VITD markedly increased
NRF2 expression (Figure 4). Although VITD plays a critical role in cell proliferation [45] and, as we
found, VITD treatment significantly increased cell viability (Figure S1), the current study suggests that
the protection of VITD against H2O2-induced toxicity is through antioxidant signalling pathways.
IL-33 is an important immune mediator in various disorders including neurodegenerative
diseases [46]. IL-33 is abundantly expressed in many cell types. Recent studies have reported that
IL-33 is expressed in human and mouse RPE and neuroretina [4,35,36]. Our data also demonstrated
that both IL-33 and ST2 are expressed in ARPE-19 cells, an observation in accordance with previous
reports [4]. Interestingly, IL-33 expression was notably decreased in aged mouse neuroretina and
RPE (Figure S3). Liu et al. (2012) reported that amyloid-β1-40 oligomer stimulated IL-33 expression
in a human RPE (D407) cell line [47]. However, the data from the present study showed that the
mRNA and protein levels of IL-33 were significantly lower in ARPE-19 cells treated with H2O2, while
both IL-33 mRNA expression and protein levels were notably increased following VITD treatment
(Figure 5C,D). Increased IL-33 expression has been reported in the vitreous and in retinal Müller
cells and mononuclear cells of AMD patients, suggesting that IL-33 may play a pathogenic role in
AMD [36]. However, Theodoropoulou et al. (2017) reported that IL-33 regulates tissue remodelling
and suppresses murine choroidal neovascularization, a clinical feature of AMD, suggesting that IL-33
may confer some protection in AMD [4]. Additionally, glia-derived IL-33 has been shown to induce
myeloid cell infiltration and enhance the recovery of the central nervous system from acute injury [14].
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In an experimental autoimmune uveitis mouse model, IL-33 slows down disease progression with
decreased retinal inflammation [35]. However, in injured mouse retina, Müller cells have been shown
to increase IL-33 production, promoting the release of inflammatory cytokines and chemokines and
the recruitment of the myeloid cells, which contribute to photoreceptor cell loss [36].
In the current study, we used co-treatment with VITD and H2O2 to assess the protection of VITD
against H2O2-induced toxicity. Other researchers have evaluated VITD protection in in vitro cell lines
by pre-treatment with VITD [20,23]. Ideally, we would also examine the protection of VITD against
H2O2-induced toxicity by pre-treatment with VITD in ARPE-19 cells. Further preclinical tests in AMD
animal models and AMD patient clinical trials are needed to verify the therapeutic potential of VITD
for AMD.
5. Conclusions
In summary, VITD can possibly protect the retina and RPE from oxidative stress, inflammation and
apoptosis through the suppression of pro-inflammatory mediators and by enhancing the antioxidant
defence capacity.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/8/9/341/s1,
Figure S1: Effects of VITD and H2O2 on cell viability. ARPE-19 cells were exposed to VITD or H2O2 for 6 hours
(A) or 24 hours (B). Cell viability was measured using MTT assay, Figure S2: (A) Expression of vitamin D receptor
(VDR) was detected in untreated (UT) and treated (H2O2 alone or H2O2 + VITD) ARPE-19 cells by end-point PCR.
PCR products were analyzed using agarose gel electrophoresis. (B) ARPE-19 cells were exposed to H2O2 or H2O2
+ VITD for 6 hours or 24 hours; expression of VDR was measured by qRT-PCR. Figure S3: Expression of IL-33 in
the retinas (A) and RPE (B) of mice at three age points was measured by qRT-PCR.
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